New blood test could spot hidden breast cancer before scans do
NCT ID NCT07069595
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is for people with a high-risk type of breast cancer (triple-negative) who still have cancer cells left after standard treatment and surgery. Researchers will use a special blood test (ctDNA) to look for tiny traces of cancer DNA that scans might miss. If the test finds cancer, participants will receive an experimental drug called Dato-DXd to try to eliminate it. The goal is to see if this approach can catch and treat recurrence earlier than usual.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Datopotamab deruxtecan (Dato-DXd)
What this could lead to
If successful, this could lead to a way to detect cancer recurrence earlier and treat it with a targeted drug, potentially improving outcomes for high-risk TNBC patients.
What could go wrong
This is a small, early-phase study (Phase II) with only 78 participants, so results may not apply to all patients. The drug Dato-DXd can cause side effects, and the ctDNA test may not always detect recurrence accurately.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UNC Lineberger Comprehensive Cancer Center
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact